Advertisement

Topics

Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments

07:30 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or “the Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced corporate developments and ...

Other Sources for this Article

Co-Diagnostics, Inc.
Andrew Benson, 801-438-1036
Investor Relations
investors@codiagnostics.com
or
Lytham Partners
Joe Diaz, Robert Blum, Joe Dorame
602-889-9700
codx@lythampartners.com

NEXT ARTICLE

More From BioPortfolio on "Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...